Literature DB >> 29126779

Squamous Cell Carcinoma Transformation from EGFR-mutated Lung Adenocarcinoma: A Case Report and Literature Review.

Hiroki Izumi1, Akira Yamasaki2, Yasuto Ueda3, Takashi Sumikawa3, Hiroyuki Maeta4, Shu Nakamoto5, Eiji Shimizu2.   

Abstract

Entities:  

Keywords:  Acquired resistance; Histologic transformation; Non–small-cell lung cancer; Osimertinib; T790M

Mesh：

Substances：

Year:  2017        PMID： 29126779     DOI： 10.1016/j.cllc.2017.10.005

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  16 in total

Review 1.  Overcoming therapy resistance in EGFR-mutant lung cancer.

Authors:  Pasi A Jänne; Tony Mok; Solange Peters; Antonio Passaro
Journal:  Nat Cancer       Date:  2021-04-15

Review 2.  Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.

Authors:  Manan P Shah; Joel W Neal
Journal:  Drugs       Date:  2022-04-12       Impact factor: 9.546

Review 3.  Lineage plasticity in cancer: a shared pathway of therapeutic resistance.

Authors:  Álvaro Quintanal-Villalonga; Joseph M Chan; Helena A Yu; Dana Pe'er; Charles L Sawyers; Triparna Sen; Charles M Rudin
Journal:  Nat Rev Clin Oncol       Date:  2020-03-09       Impact factor: 66.675

4.  Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.

Authors:  Adam J Schoenfeld; Joseph M Chan; Daisuke Kubota; Hiroki Sato; Hira Rizvi; Yahya Daneshbod; Jason C Chang; Paul K Paik; Michael Offin; Maria E Arcila; Monika A Davare; Ujwal Shinde; Dana Pe'er; Natasha Rekhtman; Mark G Kris; Romel Somwar; Gregory J Riely; Marc Ladanyi; Helena A Yu
Journal:  Clin Cancer Res       Date:  2020-01-07       Impact factor: 12.531

5.  Combined Small and Squamous Transformation in EGFR-mutated Lung Adenocarcinoma.

Authors:  Taiki Hakozaki; Miyako Kitazono; Mikio Takamori; Takahiro Kiriu
Journal:  Intern Med       Date:  2020-02-26       Impact factor: 1.271

6.  Comparison between NOD/SCID mice and BALB/c mice for patient-derived tumor xenografts model of non-small-cell lung cancer.

Authors:  Jianbin Wu; Juntao Zhang; Mei Jiang; Tianhui Zhang; Yue Wang; Ziyu Wang; Yaodong Miao; Zitong Wang; Weiying Li
Journal:  Cancer Manag Res       Date:  2018-12-06       Impact factor: 3.989

Review 7.  Pathological transition as the arising mechanism for drug resistance in lung cancer.

Authors:  Yueqing Chen; Waiying Yvonne Tang; Xinyuan Tong; Hongbin Ji
Journal:  Cancer Commun (Lond)       Date:  2019-10-01

8.  Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.

Authors:  Ashley Maynard; Caroline E McCoach; Julia K Rotow; Lincoln Harris; Franziska Haderk; D Lucas Kerr; Elizabeth A Yu; Erin L Schenk; Weilun Tan; Alexander Zee; Michelle Tan; Philippe Gui; Tasha Lea; Wei Wu; Anatoly Urisman; Kirk Jones; Rene Sit; Pallav K Kolli; Eric Seeley; Yaron Gesthalter; Daniel D Le; Kevin A Yamauchi; David M Naeger; Sourav Bandyopadhyay; Khyati Shah; Lauren Cech; Nicholas J Thomas; Anshal Gupta; Mayra Gonzalez; Hien Do; Lisa Tan; Bianca Bacaltos; Rafael Gomez-Sjoberg; Matthew Gubens; Thierry Jahan; Johannes R Kratz; David Jablons; Norma Neff; Robert C Doebele; Jonathan Weissman; Collin M Blakely; Spyros Darmanis; Trever G Bivona
Journal:  Cell       Date:  2020-08-20       Impact factor: 41.582

9.  Successful afatinib rechallenge in a patient with non-small cell lung cancer harboring EGFR G719C and S768I mutations.

Authors:  Tomomi Masuda; Noriaki Sunaga; Norimitsu Kasahara; Kazutaka Takehara; Masakiyo Yatomi; Kenichiro Hara; Yasuhiko Koga; Toshitaka Maeno; Takeshi Hisada
Journal:  Thorac Cancer       Date:  2020-06-11       Impact factor: 3.500

10.  Histologic transformation from adenocarcinoma to both small cell lung cancer and squamous cell carcinoma after treatment with gefitinib: A case report.

Authors:  Yufeng Yao; Zhouyu Zhu; Yimin Wu; Ying Chai
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.